Chiral Phosphoric Acid-Catalyzed Asymmetric Oxidation of Aryl Alkyl Sulfides
129.8, 128.5, 69.4, 54.6, 31.4, 29.5, 21.2; ESI-MS: m/z=226.9
[M+H]+; HR-MS-ESI: m/z=227.0561, calcd. for C11H15OS2
[M+H]+: 227.0559.
0.8 mLminÀ1, l=210 nm): tminor =11.4 min, tmajor =19.7 min;
[a]2D6: +79.5 (c 1.2, CHCl3); IR (KBr): n=3068, 2911, 1592,
1571, 1475, 1038, 872, 694 cmÀ1 1H NMR (300 MHz,
;
(+)-trans-2-(4’-Isopropylphenyl)-1,3-dithiane 1-oxide (5e):
White solid; yield: 87%; >99:1 dr, 78:22 er; mp 105–1078C;
HPLC (Chiralpak OD-H, hexane/i-PrOH=70/30, flow rate:
1.0 mLminÀ1, l=230 nm): tminor =7.7 min, tmajor =15.4 min;
[a]2D6: +78.4 (c 1.1, CHCl3); IR (KBr): n=2957, 1508, 1033,
CDCl3): d=7.72–7.00 (m, 4H), 4.53 (s, 1H), 3.63–3.49 (m,
1H), 2.93–2.63 (m, 3H), 2.58–2.26 (m, 2H); 13C NMR
(75 MHz, CDCl3): d=135.2, 134.9, 130.3, 129.5, 128.7, 27.0,
68.9, 54.7, 31.3, 29.4; ESI-MS (%): m/z=246.8 (100) and
248.8 (41) [M+H]+ for 35Cl and 37Cl isotopic pattern; HR-
854 cmÀ1
;
1H NMR (400 MHz, CDCl3): d=7.33 (d, J=
MS-ESI
(%):
m/z=247.0017
(100),
calcd.
for
C10H1235ClO32S2 [M+H]+: 247.0013 and m/z=248.9983 (41),
8.1 Hz, 2H), 7.25 (d, J=8.1 Hz, 2H), 4.54 (s, 1H), 3.58–3.50
(m, 1H), 2.96–2.80 (m, 2H), 2.74 (dt, J=13.2, 2.7 Hz, 1H),
2.68–2.60 (m, 1H), 2.53–2.44 (m, 1H), 2.40–2.27 (m, 1H),
1.23 (d, J=7.0 Hz, 6H); 13C NMR (100 MHz, CDCl3): d=
149.9, 130.4, 128.5, 127.1, 69.2, 54.6, 33.7, 31.3, 29.4, 23.7;
ESI-MS: m/z=254.9 [M+H]+; HR-MS-ESI: m/z=255.0874,
calcd. for C13H19OS2 [M+H]+: 255.0872.
calcd. for C10H1237ClO34S2 [M+H]+: 248.9989.
(+)-trans-2-(4’-Chlorophenyl)-1,3-dithiane 1-Oxide (5j):
White solid; yield: 99%; >99:1 dr, 85:15 er; mp 144–1468C;
HPLC (Chiralpak OD-H, hexane/i-PrOH=70/30, flow rate:
1.0 mLminÀ1, l=230 nm): tminor =10.0 min, tmajor =22.9 min;
[a]2D6: +97.7 (c 1.2, CHCl3); IR (KBr): n=3075, 2924, 1490,
1
1406, 1045, 853, 764 cmÀ1; H NMR (300 MHz, CDCl3): d=
(+)-trans-2-(2’-Fluorophenyl)-1,3-dithiane 1-oxide (5f):
White solid; yield: 76%; 93:7 dr, 80:20 er; mp 117–1188C;
HPLC (Chiralpak OD-H, hexane/i-PrOH=70/30, flow rate:
1.0 mLminÀ1, l=210 nm): tminor =9.6 min, tmajor =18.9 min;
[a]2D6: +88.5 (c 0.87, CHCl3); IR (KBr): n=3075, 2912, 1490,
7.41–7.32 (m, 4H), 4.53 (s, 1H), 3.62–3.53 (m, 1H), 2.94–
2.65 (m, 3H), 2.58–2.47 (m, 1H), 2.44–2.28 (m, 1H);
13C NMR (75 MHz, CDCl3): d=135.3, 131.8, 130.0, 129.3,
68.8, 54.7, 31.3, 29.4; ESI-MS (%): m/z=246.8 (100) and
248.8 (41) [M+H]+ for 35Cl and 37Cl isotopic pattern; HR-
1
1233, 1040, 759 cmÀ1; H NMR (400 MHz, CDCl3): d=7.61–
7.40 (m, 1H), 7.38–7.27 (m, 1H), 7.25–7.15 (m, 1H), 7.15–
7.05 (m, 1H), 5.03 (s, 1H), 3.64–3.51 (m, 1H), 2.97–2.87 (m,
1H), 2.82 (dt, J=13.2, 2.6 Hz, 1H), 2.73–2.60 (m, 1H), 2.57–
2.46 (m, 1H), 2.43–2.29 (m, 1H); 13C NMR (75 MHz,
CDCl3): d=160.8 (d, JC,F =248.3 Hz), 130.7 (d, JC,F =8.3 Hz),
129.1 (d, JC,F =1.5 Hz), 124.9 (d, JC,F =3.0 Hz), 120.9 (d,
MS-ESI
(%):
m/z=247.0010
(100),
calcd.
for
C10H1235ClO32S2 [M+H]+: 247.0013 and m/z=248.9983 (41),
calcd. for C10H1237ClO34S2 [M+H]+: 248.9989.
(+)-trans-2-(4’-Bromophenyl)-1,3-dithiane 1-oxide (5k):
White solid; yield: 98%; >99:1 dr, 85:15 er; mp 163–1658C;
HPLC (Chiralpak OD-H, hexane/i-PrOH=70/30, flow rate:
1.0 mLminÀ1, l=254 nm: tminor =10.5 min, tmajor =23.7 min;
[a]2D6: +87.6 (c 1.2, CHCl3); IR (KBr): n=3060, 2922, 1487,
J
C,F =14.3 Hz), 115.9 (d, JC,F =21.8 Hz), 61.6, 54.8, 31.4, 29.6;
ESI-MS: m/z=230.9 [M+H]+; HR-MS-ESI: m/z=231.0314,
calcd. for C10H12FOS2 [M+H]+: 231.0308.
1
1402, 1040, 851 cmÀ1; H NMR (300 MHz, CDCl3): d=7.53
(+)-trans-2-(4’-Fluorophenyl)-1,3-dithiane 1-oxide (5g):
White solid; yield: 98%; 98:2 dr, 84:16 er; mp 126–1278C;
HPLC (Chiralpak OD-H, hexane/i-PrOH=70/30, flow rate:
1.0 mLminÀ1, l=254 nm): tminor =9.2 min. tmajor =21.2 min;
[a]2D6: +71.4 (c 0.94, CHCl3); IR (KBr): n=3056, 2914, 1599,
(d, J=8.3 Hz, 2H), 7.29 (d, J=8.3 Hz, 2H), 4.52 (s, 1H),
3.62–3.49 (m, 1H), 2.93–2.62 (m, 3H), 2.57–2.45 (m, 1H),
2.44–2.25 (m, 1H); 13C NMR (75 MHz, CDCl3): d=132.3,
132.1, 130.2, 123.5, 68.8, 54.6, 31.2, 29.4; ESI-MS (%): m/z=
290.7 (94) and 292.7 (100) [M+H]+ for 79Br and 81Br isotop-
ic pattern; HR-MS-ESI (%): m/z=290.9510 (94), calcd. for
C10H1279BrO32S2 [M+H]+: 290.9507 and m/z=292.9488
(100), calcd. for C10H1281BrO34S2 [M+H]+: 292.9486.
1
1509, 1224, 1038, 850 cmÀ1; H NMR (300 MHz, CDCl3): d=
7.47–7.35 (m, 2H), 7.16–7.03 (m, 2H), 4.54 (s, 1H), 3.63–
3.50 (m, 1H), 2.94–2.83 (m, 1H), 2.81–2.63 (m, 2H), 2.59–
2.47 (m, 1H), 2.45–2.27 (m, 1H); 13C NMR (75 MHz,
CDCl3): d=163.1 (d, JC,F =247.5 Hz), 130.5 (d, JC,F =8.3 Hz),
129.2 (d, JC,F =3.0 Hz), 116.1 (d, JC,F =21.8 Hz), 68.7, 54.7,
31.4, 29.4; ESI-MS: m/z=230.9 [M+H]+; HRMS-ESI: m/
z=231.0304, calcd. for C10H12FOS2 [M+H]+: 231.0308.
(+)-trans-2-(2’-Chlorophenyl)-1,3-dithiane 1-oxide (5h):
White solid; yield: 95%; 90:10 dr, 81:19 er; mp 134–1368C;
HPLC (Chiralpak OD-H, hexane/i-PrOH=70/30, flow rate:
0.8 mLminÀ1, l=210 nm): tminor =12.1 min, tmajor =17.4 min;
[a]2D6: +78.3 (c 1.1, CHCl3); IR (KBr): n=3060, 2916, 1474,
(+)-trans-2-(3’-Nitrophenyl)-1,3-dithiane 1-oxide (5l):
White solid; yield: 94%; >99:1 dr, 87:13 er; mp 153–1558C;
HPLC (Chiralpak OD-H, hexane/i-PrOH=70/30, flow rate:
0.8 mLminÀ1, l=254 nm): tminor =19.2 min, tmajor =31.0 min;
[a]2D6: +70.7 (c 1.0, CHCl3); IR (KBr): n=3064, 2916, 1531,
1
1352, 1037, 692 cmÀ1; H NMR (300 MHz, CDCl3): d=8.40–
8.15 (m, 2H), 7.77 (d, J=7.7 Hz, 1H), 7.61 (t, J=8.0 Hz,
1H), 4.70 (s, 1H), 3.69–3.56 (m, 1H), 3.03–2.68 (m, 3H),
2.65–2.52 (m, 1H), 2.51–2.32 (m, 1H); 13C NMR (75 MHz,
CDCl3): d=148.4, 135.5, 134.9, 130.1, 124.2, 123.8, 68.5, 54.7,
31.2, 29.4; ESI-MS: m/z=257.8 [M+H]+; HR-MS-ESI: m/
z=258.0254, calcd. for C10H12NO3S2 [M+H]+: 258.0253.
(+)-trans-2-(4’-Nitrophenyl)-1,3-dithiane 1-oxide (5m):
White solid; yield: 79%; >99:1 dr, 83:17 er; mp 162–
1638C;HPLC (Chiralpak OD-H, hexane/i-PrOH=70/30,
1
1427, 1032, 753 cmÀ1; H NMR (300 MHz, CDCl3): d=7.63–
7.48 (m, 1H), 7.48–7.39 (m, 1H), 7.39–7.22 (m, 2H), 5.28 (s,
1H), 3.67–3.52 (m, 1H), 3.04–2.76 (m, 2H), 2.71–2.60 (m,
1H), 2.60–2.47 (m, 1H), 2.46–2.27 (m, 1H); 13C NMR
(75 MHz, CDCl3): d=134.9, 131.4, 130.1, 130.0, 129.1, 127.7,
65.1, 54.8, 31.6, 29.7; ESI-MS (%): m/z=246.8 (100) and
248.8 (41) [M+H]+ for 35Cl and 37Cl isotopic pattern; HR-
flow rate: 1.0 mLminÀ1, l=254 nm): tminor =19.4 min, tmajor
37.5 min; [a]2D6: +121.4 (c 0.92, CHCl3); IR (KBr): n=3130,
2935, 1604, 1526, 1354, 1041, 867, 695 cmÀ1 1H NMR
=
MS-ESI
(%):
m/z=247.0013
(100),
calcd.
for
C10H1235ClO32S2 [M+H]+: 247.0013 and m/z=248.9987 (41),
;
calcd. for C10H1237ClO34S2 [M+H]+: 248.9989.
(300 MHz, CDCl3): d=8.26 (d, J=8.6 Hz, 2H), 7.61 (d, J=
8.6 Hz, 2H), 4.68 (s, 1H), 3.68–3.56 (m, 1H), 3.00–2.70 (m,
3H), 2.64–2.52 (m, 1H), 2.51–2.32 (m, 1H); 13C NMR
(75 MHz, CDCl3): d=148.2, 140.5, 129.8, 124.1, 68.7, 54.8,
(+)-trans-2-(3’-Chlorophenyl)-1,3-dithiane 1-oxide (5i):
White solid; yield: 99%; >99:1 dr, 82:18 er; mp 118–1198C;
HPLC (Chiralpak OD-H, hexane/-iPrOH=70/30, flow rate:
Adv. Synth. Catal. 2012, 354, 1012 – 1022
ꢁ 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
1019